Haghdoost Mehdi, Taghizadeh Sepehr, Montazer Majid, Poorshahverdi Parinaz, Ramouz Ali, Fakour Sanam
Department of Infectious Diseases, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran.
Caspian J Intern Med. 2017 Summer;8(3):165-171. doi: 10.22088/cjim.8.3.165.
A decreased rate of successful (H.pylori) infection treatment has revealed serious demand for more effective regimens to eradicate infection. Therefore, probiotics have recently been considered to increase the rate of antibiotic regimens efficacy in infections. In current randomized controlled trial, we evaluated the effect of double strain probiotic combination with standard triple therapy (STT), in the eradication rate of infection.
In current randomized placebo-control study, all patients (176 subjects) underwent the STT for 10 days. However, the study group received triple therapy for the eradication of with supplement of probiotic for 4 weeks and placebo was administered to control group, as well. Adverse effects of the antibiotic regimen were recorded for all patients. Six weeks after the cessation of probiotic intake, all patients underwent with fecal antigen of test, followed by a recurrence evaluation six months later.
There was no significant difference in demographic data and presenting symptoms between the study groups. The eradication rate of infection was significantly higher in probiotic group (78.4%), compared to that of placebo group (64.8%) (P=0.033). In addition, adverse events were significantly less prevalent in patients that received probiotic (P=0.047). Nonetheless, there was no significant difference in terms of infection recurrence during a 6-month follow-up (P=0.07).
Double strain probiotic in combination with STT increased the eradication rate of infection, while the adverse events due to antibiotic therapy decreased.
幽门螺杆菌(H.pylori)感染治疗成功率的下降表明,迫切需要更有效的治疗方案来根除感染。因此,益生菌最近被认为可以提高抗生素治疗方案对幽门螺杆菌感染的疗效。在当前的随机对照试验中,我们评估了双菌株益生菌与标准三联疗法(STT)联合使用对幽门螺杆菌感染根除率的影响。
在当前的随机安慰剂对照研究中,所有患者(176名受试者)接受了10天的标准三联疗法。然而,研究组在根除幽门螺杆菌的三联疗法基础上补充益生菌4周,对照组也给予安慰剂。记录所有患者抗生素治疗方案的不良反应。在停止摄入益生菌六周后,所有患者接受粪便抗原检测,六个月后进行复发评估。
研究组之间的人口统计学数据和出现的症状没有显著差异。益生菌组幽门螺杆菌感染的根除率(78.4%)显著高于安慰剂组(64.8%)(P=0.033)。此外,接受益生菌治疗的患者不良事件的发生率显著较低(P=0.047)。尽管如此,在6个月的随访期间,感染复发率没有显著差异(P=0.07)。
双菌株益生菌与标准三联疗法联合使用可提高幽门螺杆菌感染的根除率,同时降低抗生素治疗引起的不良事件。